nach oben

Heart Failure Reviews

Erschienen in:

01.01.2010

Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure

verfasst von: Navneet S. Rehsia, Naranjan S. Dhalla

Erschienen in: Heart Failure Reviews | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

It is now becoming clear that two major systems namely the sympathetic nervous system and the renin-angiotensin system are activated in response to ischemic injury; these result in the elevation of plasma catecholamines and angiotensin II during the development of myocardial infarction as well as congestive heart failure. Although plasma levels of several other hormones including aldosterone, endothelin, vasopressin, natriuretic peptides, growth factors and inflammatory cytokines are also increased in heart failure, their relationship with changes in catecholamine and/or angiotensin levels as well as their significance for the induction of congestive heart failure are poorly understood. In this article we have examined the evidence regarding the role of endothelin and vasopressin in the pathogenesis of cardiac hypertrophy and congestive heart failure in addition to evaluating the significance of their antagonism by using their receptor blockade for treatment of congestive heart failure. Endothelin appears to maintain blood pressure by its vasoconstricting action whereas vasopressin primarily produces similar effect by retention of body fluid. Myocardium is also known to express both ET-A and ET-B receptors in addition to V₁ and V₂ receptors for vasopressin, which have been shown to induce cardiac remodeling. Out of various ET-1 receptor antagonists, which are available, a non-selective endothelin receptor antagonist, bosentan, as well as an ET-A receptor antagonist, BQ-123, seem most promising for the treatment of congestive heart failure. Likewise, vasopressin antagonists such as a non-selective antagonist, conivaptan, as well as V₂ selective antagonist, tolvaptan, may prove highly valuable for the therapy of this condition. Since most of the existing interventions are helpful in treating patients with congestive heart failure only partially, there appears to be a real challenge for developing some combination therapy for the treatment of congestive heart failure.

Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB et al (2002) Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 106:3068–3072PubMed

Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Wilson M et al (2008) Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Committee. Circulation 117:e25–e146PubMed

Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda R (1999) Heart failure survival among older adults in United States: a poor prognosis for an emerging epidemic in the medicare population. Arch Intern Med 159:2225–2226

Hunt SA, Abraham WT, Francis GS, Konstam MA, Silver MA, Yancy CW et al (2005) American College of Cardiology, American Heart Association Task Force on Practice Guidelines. ACC/AHAguideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 46:e1–e82PubMed

Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C et al (2007) A comprehensive view of sex-specific issues related to cardiovascular diseases. Can Med Assoc J 176:S1–S44

Braunwald E (2001) Congestive heart failure: a half century perspective. Eur Heart J 22:825–836PubMed

Cleutjans JPM, Kandala JC, Guarda E, Guntaka RV, Weber KT (1995) Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 27:1281–1292

Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo S (1992) Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. J Biol Chem 267:10551–10560PubMed

Schomig A (1990) Catecholamines in myocardial ischemia. Systemic and cardiac release. Circulation 82:1113–1122

10.

Floras JS (2003) Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 177:391–398PubMed

11.

Kara T, Narkiewicz K, Somers VK (2003) Chemoreflexes—physiology and clinical implications. Acta Physiol Scand 177:377–384PubMed

12.

Esler M, Jennings G, Korner P, Blombery P, Sacharias N, Leonard P (1984) Measurements of total and organ-specific norepinephrine kinetics in humans. Am J Physiol 247:E21–E28PubMed

13.

Graham LN, Smith PA, Stoker JB, Mackintosh AF, Mary DASG (2002) Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation 106:793–797PubMed

14.

Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Eng J Med 341:577–585

15.

Katz AM (2003) Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. J Cell Mol Med 7:1–10PubMed

16.

Opie LH (2008) Mechanisms of cardiac contraction and relaxation. In: Braunwaldt E (ed) Heart disease: a textbook of cardiovascular medicine, 8th edn. Saunders, Philadelphia, pp 509–537

17.

Persson PB (2003) Renin: origin secretion and synthesis. J Physiol 552:667–671PubMed

18.

Ju H, Zhao S, Tappia PS, Panagia V, Dixon IMC (1998) Expression of G_qα and PLC-β in scar and border tissue in heart failure due to myocardial infarction. Circulation 97:892–899PubMed

19.

Baker KM, Aceto JF (1990) Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol Heart Circ Physiol 259:H610–H618

20.

Ollivier JP, Bouchet VA (1992) Prospects of cardioreparation. Am J Cardiol 70:27C–36CPubMed

21.

Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JF, Apstein CS, Lorell BH (1993) Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 87:1328–1339PubMed

22.

Bonvalet JP, Alfaidy N, Farman N, Lombes M (1995) Aldosterone: intracellular receptors in human heart. Eur Heart J 16:92–97PubMed

23.

Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K et al (2001) Aldosterone production is activated in failing ventricle in humans. Circulation 103:72–77PubMed

24.

Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 102:2700–2706PubMed

25.

Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M et al (2001) Aldosterone induces angiotensin-converting enzyme gene expression in cultured neonatal rat cardiomyocytes. Circulation 104:137–139PubMed

26.

Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T et al (1989) Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophysics Res Commun 159:1435–1440

27.

Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T et al (1989) Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 160:93–100

28.

Moreau P, d’ Uscio L, Shaw S, Takase H, Barton M, Luscher TF (1997) Angiotensin II increases tissue endothelin and increases vascular hypertrophy: reversal by ET-A receptor antagonist. Circulation 96:1593–1597PubMed

29.

Francis GS (2001) Pathophysiology of chronic heart failure. Am J Med 110:37S–46SPubMed

30.

Kawaguchi H, Sawa H, Yasuda H (1991) Effect of endothelin on angiotensin converting enzyme in cultured pulmonary artery endothelial cells. J Hypertens 9:171–174PubMed

31.

Cozza EN, Gomez-Sanchez CE, Foecking MF, Chiou S (1989) Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Investig 84:1032–1035PubMed

32.

Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMed

33.

Herizi A, Jover B, Bouriquet N, Mimran A (1998) Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 31:10–14PubMed

34.

Dostal DE, Baker KM (1998) Angiotensin and endothilin: messengers that couple ventricular stretch to Na⁺/H⁺ exchanger and cardiac hypertrophy. Circ Res 83:870–873PubMed

35.

Holmes CL, Patel BM, Russell JA, Walley KR (2001) Physiology of vasopressin relevant to management of septic shock. Chest 120:989–1002PubMed

36.

Fukuzawa J, Haneda T, Kikuchi K (1999) Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V₁ receptor. Mol Cell Biochem 195:93–98PubMed

37.

Fan YH, Zhao LY, Zheng QS, Dong H, Wang HC, Yang XD (2007) Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-κB activation and its relation with myocardial fibrosis. Life Sci 81:327–335PubMed

38.

Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91:988–998PubMed

39.

Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35:569–582PubMed

40.

Suttner SW, Boldt J (2004) Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care 10:336–341PubMed

41.

Lucas KA, Pitari GM, Kazerounian S, Park J, Waldman SA et al (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375–414PubMed

42.

Hickey KA, Rubanyi G, Paul RJ, Highsmith RF (1985) Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 248:C550–C556PubMed

43.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415PubMed

44.

Haynes WG, Webb DJ (1993) The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci 84:485–500PubMed

45.

Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R et al (2004) Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 15:237–239

46.

Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K et al (1994) Pharmacological characterization of bosentan, a new potent orally-active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228–235PubMed

47.

Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G et al (2003) Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated failure. J Am Coll Cardiol 42:140–147PubMed

48.

Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K et al (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by 3 separate genes. Proc Natl Acad Sci USA 86:2863–2867PubMed

49.

Hirata Y, Kanno K, Watanabe TX, Kumagaye S, Nakajima K, Kimura T, Sakakibara S, Marumo F (1990) Receptor binding and vasoconstrictor activity of big endothelin. Eur J Pharmacol 176:225–228PubMed

50.

Kedzierski RM, Yanagisawa M (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41:851–876PubMed

51.

Ikeda K, Emoto N, Raharjo SB, Nurhantari Y, Saiki K, Yokohama M et al (1999) Molecular identification and characterization of novel membrane bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J Biol Chem 274:32469–32477PubMed

52.

Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S et al (2000) Disruption of ECE-1 and ECE-2 reveals a role of endothelin-converting enzyme-2 in murine cardiac development. J Clin Investig 105:1373–1382PubMed

53.

Ortmann J, Nett PC, Celeiro J, Traupe T, Tornillo L, Hofmann-Lehmann R et al (2005) Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells. Biochem Biophys Res Commun 334:689–695PubMed

54.

Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T (1989) The human preproendothelin-1 gene: complete nucleotide sequence and regulation of expression. J Biol Chem 264:14954–14959PubMed

55.

Haynes WG, Webb DJ (1998) Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16:1081–1098PubMed

56.

Haynes WG, Webb DJ (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344:852–854PubMed

57.

Russel FD, Skepper JN, Davenport AP (1998) Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme. Circ Res 83:314–321

58.

Davenport AP (2002) International union of pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54:219–226PubMed

59.

Schiffrin EL (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14:83S–89SPubMed

60.

Luscher TF, Barton M (2000) Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102:2434–2440PubMed

61.

Molenaar P, O’Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C et al (1993) Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 72:526–538PubMed

62.

Russell FD, Skepper JN, Davenport AP (1997) Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography. J Cardiovasc Pharmacol 29:820–826PubMed

63.

Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ (2000) Contractile and arrhythmic effects of endothelin receptor agonist in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther 292:449–459PubMed

64.

Liu J, Chen R, Casley DJ, Nayler WN (1990) Ischemia and reperfusion increase ¹²⁵I-labelled endothelin-1 binding in rat cardiac membranes. Am J Physiol Heart Circ Physiol 258:H829–H835

65.

Nambi P, Pullen M, Contino LC, Brooks DP (1990) Upregulation of renal endothelin receptors in rats with cyclosporin A-induced nephrotoxicity. Eur J Pharmacol 187:113–116PubMed

66.

Hirata Y, Yoshimi H, Takaichi S, Yanagisawa M, Masaki T (1988) Binding and receptor down-regulation of novel vasoconstrictor endothelin in cultured rat vascular smooth cells. FEBS Lett 239:13–17PubMed

67.

Roubert P, Gillard V, Plas P, Guillon JM, Chabrier PE, Braquet P (1989) Angiotensin II and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells. Biochem Biophys Res Commun 164:809–815PubMed

68.

Golfman LS, Hata T, Beamish RE, Dhalla NS (1993) Role of endothelin in heart function and disease. Can J Cardiol 9:635–653PubMed

69.

Sugden PH (2003) An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol 35:871–886PubMed

70.

Martinez-Miguel P, Roach V, Zaragoza C, Valdivielso JM, Rodriguez-Puyol M, Rodriguez-Puyol D et al (2009) Endothelin-converting enzyme-1 increases in atherosclerotic mice: potential role of oxidized low density lipoproteins. J Lipid Res 50:364–376PubMed

71.

Cerdeira AS, Bras-Silva C, Leite-Moreira AF (2008) Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases. Rev Port Cardiol 27:385–408PubMed

72.

Ezra D, Goldstein RE, Czaja JF, Feuerstein GZ (1989) Lethal ischemia due to intracoronary endotelin in pigs. Am J Physiol Heart Circ Physiol 257:H339–H343

73.

Grover GJ, Dzwonczyk S, Parham CS (1993) The endothelin-1 receptor antagonist BQ-123 reduces the infarct size in canine model of coronary occlusion and reperfusion. Cardiovasc Res 27:1613–1618PubMed

74.

Stewart DJ, Kubac G, Costello K, Cernacek P (1991) Increased plasma endothelin-1 in early hours of acute myocardial infarction. J Am Coll Cardiol 18:38–43PubMed

75.

Halcox JPJ, Nour KRA, Zalos G, Quyyumi AA (1991) Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET-A receptor blockade. Circ Res 89:969–976

76.

Araki M, Hasegawa K, Iwai-Kanai E, Fujita M, Sawamura T, Kakita T et al (2000) Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes. J Am Coll Cardiol 36:1411–1418PubMed

77.

Wang L, Gout I, Proud CG (2001) Cross-talk between the ERK and p70 S6 kinase (S6 K) signaling pathways. J Biol Chem 276:32670–32677PubMed

78.

Ren A, Yan X, Lu H, Shi J, Yin Y, Bai J et al (2008) Antagonism of endothelin-1 inhibits hypoxia-induced apoptosis in cardiomyocytes. Can J Physiol Pharmacol 86:536–540PubMed

79.

Kakita T, Hasegawa K, Iwai-Kanai E, Adachi S, Morimoto T, Wada H et al (2001) Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes. Circ Res 88:1239–1246PubMed

80.

Klee CB, Ren H, Wang X (1998) Regulation of the calmodulin-stimulated protein phosphate, calcineurin. J Biol Chem 273:13367–13370PubMed

81.

Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J et al (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215–228PubMed

82.

Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y (1996) Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384:353–355PubMed

83.

Iwai-Kanai E, Hasegawa K (2004) Intracellular signaling pathways for norepinephrine- and endothelin-1-mediated regulation of myocardial cell apoptosis. Mol Cell Biochem 259:163–168PubMed

84.

Enseleit F, Luscher TF, Ruschitzka F (2008) Darusentan: a new perspective for treatment of resistant hypertension? Expert Opin Investig Drugs 17:1255–1263PubMed

85.

Raichlin E, Prasad A, Mathew V, Kent B, Holmes DR Jr, Pumper GM, Nelson RE, Lermon LO, Lermon A (2008) Efficacy and safety of atresentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 52:522–528PubMed

86.

Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S et al (1995) Selective blockade of endothelin subtype-A receptor decreases early atherosclerosis in hamsters fed cholestrol. Am J Pathol 146:819–826PubMed

87.

Dhaun N, Goddard J, Webb DJ (2006) The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17:943–955PubMed

88.

Babaei S, Picard P, Ravandi A, Monge JC, Lee TC, Stewart DJ et al (2000) Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 48:158–167PubMed

89.

Ishikawa T, Li LM, Shinmi O, Kimura S, Yanagisawa M, Goto K et al (1991) Characteristics of binding of endothelin-1 and endothelin-2 to rat hearts. Development changes in mechanical responses and receptor subtypes. Circ Res 69:918–926PubMed

90.

Edwards RM, Trizna W, Ohlstein EH (1990) Renal microvascular effects of endothelin. Am J Physiol 259:F217–F221PubMed

91.

Lopez-Farre A, Montanes I, Millas I, Lopez-Novoa JM (1989) Effect of endothelin on renal functions in rats. Eur J Pharmacol 163:187–189PubMed

92.

Kohan DE, Fiedorek FT (1991) Endothelin synthesis by the rat inner medullary collecting duct cells. J Am Soc Nephrol 2:150–155PubMed

93.

Terada Y, Tomita K, Nonoguchi H, Marumo F (1992) Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Investig 90:107–112PubMed

94.

Rakugi H, Nakamaru M, Saito H, Higaki J, Ogihara T (1988) Endothelin inhibits renin release from isolated rat glomeruli. Biochem Biophys Res Commun 155:1244–1247PubMed

95.

Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Webb DJ et al (2004) Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure. Circulation 109:1186–1193PubMed

96.

Kuwaki T, Kurihara H, Cao W-H, Kurihara Y, Kumada M, Unekawa M et al (1997) Physiological role of brain endothelin in the central autonomic control: from neuron to knockout mouse. Prog Neurobiol 51:545–579PubMed

97.

Nishimura M, Takahashi H, Matsusawa M, Ikegaki I, Sakamoto M, Nakanishi T et al (1991) Chronic intracerebroventricular infusions of endothelin elevate arterial pressure in rats. J Hypertens 9:71–76PubMed

98.

Spyer KM, McQueen DS, Dashwood MR, Sykes RM, Daly MB, Muddle JR (1991) Localisation of [¹²⁵I] endothelin binding sites in the region of the carotid bifurcatioin and brainstem of the cat: possible baro-and chemoreceptor involvement. J Cardiovasc Pharmacol 17:S385–S389PubMed

99.

Koseki C, Imai M, Hirata Y, Yanagisawa M, Masaki T (1989) Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? Am J Physiol Regul Physiol 256:R858–R866

100.

Fakuda Y, Hirata Y, Yoshimi H, Kojima T, Kobayashi Y, Yanagisawa M et al (1988) Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem Biophys Res Commun 155:167–172

101.

Boarder MR, Marriot DB (1989) Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells. J Cardiovasc Pharmacol 13:S223–S224PubMed

102.

McMurray JJV, Teerlink JR, Cotter G et al (2007) Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. J Am Med Assoc 298:2009–2019

103.

Coletta AP, Cleland JGF (2001) Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology—WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 3:747–750PubMed

104.

Louis A, Cleland JGF, Crabbe S, Ford S, Thackray S, Clark A et al (2001) Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholestrol in heart failure: highlights of the Scientfic Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 3:381–387PubMed

105.

O’Connor CM, Gattis WA, Adams KF, Hasselblad V, Teerlink J, Gheorghiade M et al (2003) Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous Tezosentan Study (RITZ-4). J Am Coll Cardiol 41:1452–1457PubMed

106.

Kaluski E, Kobrin I, Zimlichman R, Marmor A, Vered Z, Cotter G et al (2003) RITZ-5: randomized intravenous tezosentan (an endothelin-a/b antagonist) for the treatment of pulmonary edema: a progressive, multicenter, double blind, placebo controlled study. J Am Coll Cardiol 41:204–210PubMed

107.

Clozel M, Qiu C, Qiu CS, Hess P, Colzel JP (2002) Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 39:142–147PubMed

108.

Breu V, Ertel SI, Roux S, Clozel M (1998) The pharmacology of bosentan. Expert Opin Investig Drug 7:1173–1192

109.

Packer M, McMurray J, Massie BM, Anderson S, Swedberg K, Demets DL et al (2005) Clinical effects of endothellin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11:12–20PubMed

110.

Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G (1997) Chronic endothelin receptor blockade attenuates progressive ventricular dilatation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96:3963–3973PubMed

111.

Prasad SK, Dargie HJ, Smith GC, Barlow MM, Grothues F, Groenning BA, Cleland JGF, Pennell DJ (2006) Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart 92:798–803PubMed

112.

Nguyen QT, Cernacek P, Sirois MG, Calderone A, Lapointe N, Stewart DJ, Rouleau JL (2001) Long term effects of nonselective endothelin A and B receptor antagonism in post-infarction rat: importance and timing. Circulation 104:2075–2081PubMed

113.

Epstein BJ (2008) Efficacy and safety of darusentan: a novel endothelin receptor antagonist. Ann Pharmacother 42:1060–1069PubMed

114.

Miyauchi T, Fujimori A, Maeda S, Iemetsu M, Sakai S, Yamaguchi I et al (2004) Chronic administration of an Endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure. J Cardiovasc Pharmacol 44:S64–S67PubMed

115.

Nishida M, Hayashi T, Ieshima M, Eshiro K, Akiyoshi K, Matsumura Y et al (2005) Selective endothelin ET-B receptor antagonist improves left ventricular function but exaggerates degeneration of cardiomyocytes in J2 N-k hamsters. Circ J 69:107–113PubMed

116.

Cowburn PJ, Cleland JGF, McDonagh TA, McArthur JD, Dargie HJ, Morton JJ (2005) Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur J Heart Fail 7:37–42PubMed

117.

Mylona P, Cleland JGF (1999) Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur J Heart Fail 1:197–200PubMed

118.

Kalra PR, Moon JC, Coats AJ (2002) Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85:195–197PubMed

119.

Anand I, McMurray J, Cohn JN, Konstam MA, Ruschitzka F, Luscher TF et al (2004) Long-term effects of darusentan on left-ventricular remodeling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 364:347–354PubMed

120.

Hu K, Gaudron P, Schmidt TJ, Hoffmann KD, Ertl G (1998) Aggravation of left ventricular remodeling by a novel specific endothelin ET-A antagonist EMD94246 in rats with myocardial infarction. J Cardiovasc Pharmacol 32:505–508PubMed

121.

Narin C, Kiris I, Gulmen S, Toy H, Yilmaz N, Sutcu R (2008) Endothelin receptor blockade with tezosentan ameliorates myocardial injury induced by abdominal aortic ischemia–reperfusion. Tohoku J Exp Med 216:267–276PubMed

122.

Trescher K, Bauer M, Dietl W, Hallstrom S, Wick N, Wolfsberger M, Ullrich R, Jurgens G, Wolner E, Podesser BK (2009) Improved myocardial protection in the failing heart by selective endothelin-A receptor blockade. J Thorac Cardiovasc Surg 137:1005–1011PubMed

123.

Turner RA, Pierce JG, Du Vigneaud V (1951) The purification and the amino acid content of vasopressin preparations. J Biol Chem 191:21–28PubMed

124.

Davoll H, Turner RA, Pierce JG, Du Vigneaud V (1951) An investigation of the free amino groups on oxytocin and desulfurized oxytocin preparations. J Biol Chem 193:363–370PubMed

125.

Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Yusuf S (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with or without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724–1729PubMed

126.

Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Eng J Med 305:263–266

127.

Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1:1385–1390PubMed

128.

Xu DL, Martin PY, Ohara M, Pattison T, Morris K, Kim JK et al (1997) Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Investig 99:1500–1505PubMed

129.

Verbalis JG (2006) AVP receptor antagonist as aquaretics: review and assessment of clinical data. Cleve Clin J Med 73:S24–S33PubMed

130.

Guyton AC (2006) The body fluids and kidneys. In: Guyton AC, Hall JE (eds) Textbook of medical physiology. Saunders, Philadelphia, pp 291–414

131.

Kamoi K, Ishibashi M, Yamaji T (1997) Interaction of osmotic and nonosmotic stimuli in regulation of vasopressin secretion in hypo-osmolar state of man. Endocr J 44:311–317PubMed

132.

Hupf H, Grimm D, Riegger GA, Schunkert H (1999) Evidence of vasopressin system in the rat heart. Circ Res 84:365–370PubMed

133.

Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS (1985) Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol 248:396–402

134.

Brooks VL, Keil LC, Reid IA (1986) Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res 58:829–838PubMed

135.

Carmichael MC, Kumar R (1994) Molecular biology of vasopressin receptors. Semin Nephrol 14:341–348PubMed

136.

Baertschi AJ, Friedli M (1985) A novel type of vasopressin receptor on anterior pituitary corticotrophs. Endocrinol 116:499–502

137.

Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab 11:406–410PubMed

138.

Nielson S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D (1999) Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 10:647–663

139.

Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM (2000) Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V₂ receptors and cAMP. J Clin Investig 106:107–116PubMed

140.

Xu YJ, Gopalakrishnan V (1991) Vasopressin increases cytosolic free Ca²⁺ in the neonatal rat cardiomyocyte. Evidence for V₁ subtype receptors. Circ Res 69:239–245PubMed

141.

Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K (2000) Hypertrophic growth of cultured neotatal rat heart cells mediated by vasopressin V_1a receptor. Eur J Pharmacol 391:39–48PubMed

142.

Jackson EK (2006) Vasopressin and other agents affecting the renal conservation of water. In: Brunton LL (ed) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn. McGraw Hill, New York, pp 771–788

143.

Snyder HM, Noland TD, Breyer MD (1992) cAMP-dependent protein kinase mediates hydro-osmotic effect of vasopressin in collecting duct. Am J Physiol 263:C147–C153PubMed

144.

Manning M, Sawyer WH (1989) Discovery, development and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 114:617–632PubMed

145.

Mah SC, Opperman JR, Baum HP, Hofbauer KG (1988) Biologic response to chronic blockade of vasopressin receptors in Spragur–Dawley rats. J Pharmacol Exp Ther 245:1021–1027PubMed

146.

Thibonnier M (1988) Use of vasopressin antagonists in human diseases. Kidney Intl Suppl 26:S48–S51

147.

Yamamura Y, Ogawa H, Yamashita H, Chihara T, Tominaga M, Yabuuchi Y et al (1992) Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V₂ receptor antogonist. Br J Pharmacol 105:787–791PubMed

148.

Lee CR, Watkins ML, Patterson H, Gattis W, Gheorghiade M, Adams KF et al (2003) Vasopressin: a new target for the treatment of heart failure. Am Heart J 146:9–18PubMed

149.

Schrier RW, Martin PY (1998) Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 449:415–426PubMed

150.

Chin MH, Goldman L (1996) Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 156:1814–1820PubMed

151.

Goldsmith SR, Francis GS, Cowley AW, Goldenberg IF, Crohn JN (1986) Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8:779–783PubMedCrossRef

152.

Goldsmith SR (1987) Vasopressin as vasopressor. Am J Med 82:1213–1219PubMed

153.

Tahara A, Tomura Y, Wada K, Kusayama T, Yatsu T, Tanaka A et al (1998) Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 38:198–205PubMed

154.

Klein L, O’Connor CM, Leimberger JD, Adams KF, Califf RM, Gheorghiade M et al (2005) Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study. Circulation 111:2454–2460PubMed

155.

Gheorghiade M, Gattis WA, O’Connor CM, Klapholz M, Orlandi C, Ghali JK et al (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. J Am Med Assoc 291:1963–1971

156.

Gheorghiade M, Konstam MA, Zimmer C, Burnett JC, Udelson JE, Orlandi C et al (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. The EVEREST clinical status trials. J Am Med Assoc 297:1332–1342

157.

Konstam MA, Gheorghiade M, Ouyang J, Cook T, Zimmer C, Orlandi C et al (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome trial. J Am Med Assoc 297:1319–1331

158.

Udelson JE, McGrew FA, Flores E, Ibrahim H, Orlandi C, Konstan MA et al (2007) Multicenter, randomized, double-blind placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 9:2151–2159

159.

Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW (2006) Aquaretic effects of lixivaptan, an oral, non-peptide, selective V₂ receptor vasopressin antagonist, in New York Heart Association class II and III chronic heart failure patients. J Am Coll Cardiol 47:1615–1621PubMed

160.

Veeraveedu PT, Watanabe K, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y et al (2009) Effects of V₂-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol 75:1322–1330

161.

Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Saruta T et al (1994) Effects of oral AVP receptor antagonist OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol Heart Circ Physiol 267:H2245–H2254

162.

Burrell LM, Phillips PA, Risvanis J, Chan RK, Aldred KL, Johnston CI (1998) Long-term effects of nonpeptide vasopressin V₂ antagonist OPC-31260 in heart failure in the rat. Am J Physiol Heart Circ Physiol 275:H176–H182

163.

Nishikimi T, Kawano Y, Saito Y, Matsuoka H (1996) Effect of long-term treatment with selective vasopressin V₁ and V₂ receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 27:275–282PubMed

164.

Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Konstan MA et al (2001) Acute hemodynamic effects of conivaptan, a dual V_1a and V₂ vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417–2423PubMed

165.

Yatsu T, Tomura Y, Tahara A, Wada K, Kusayama T, Honda K et al (1999) Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V_1a and V₂ receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 376:239–246PubMed

166.

Goldsmith SR, Elkayam U, Haught W, Barve A, He W (2008) Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 14:641–648PubMed

167.

Clair MJ, King MK, Goldberg AT, Hendrick JW, Nisato D, Spinale FG et al (2000) Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive cardiac failure. J Pharmacol Exp Ther 293:852–860PubMed

Titel: Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure
verfasst von: Navneet S. Rehsia
Naranjan S. Dhalla
Publikationsdatum: 01.01.2010
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 1/2010
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-009-9152-z

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure

Abstract

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

How does the heart (not) die? The role of autophagy in cardiomyocyte homeostasis and cell death

Cell delivery and tracking in post-myocardial infarction cardiac stem cell therapy: an introduction for clinical researchers

Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics

George C. Sutton, Kanu Chatterjee: Heart failure: current clinical understanding

Architecture of the left ventricle: insights for optimal surgical ventricular restoration

Echocardiography in the assessment of left ventricular longitudinal systolic function: current methodology and clinical applications

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

Update Kardiologie